| 摘要: |
| ［摘要］ 目的 检测癌-睾丸抗原NY-SAR-35基因在视网膜母细胞瘤（RB）中的表达，探讨其作为RB特异性免疫治疗靶抗原的可能性。方法 利用逆转录-聚合酶链反应方法，检测NY-SAR-35基因在15例RB组织、12例非肿瘤病变视网膜和22例其他正常眼部组织（眼睑皮肤12例、眼肌5例、结膜5例）中的表达，随机抽取RT-PCR阳性产物直接进行DNA测序，并将其表达结果与临床相关指标（性别、年龄、病理分型、肿瘤大小、临床分期）进行统计学分析，以探讨这一类肿瘤抗原的临床意义。结果 在15例RB组织中，NY-SAR-35基因的表达率为60%（95%CI：35.2%～84.8%）；在非肿瘤病变视网膜组织和其他正常组织中，无一例表达NY-SAR-35基因；其表达与临床相关指标（性别、年龄、病理分型、肿瘤大小、临床分期）无关（P>0.05）。结论 NY-SAR-35基因可特异性地表达于RB中，可能成为RB特异性免疫治疗的靶抗原，具有进一步研究开发的前景。 |
| 关键词: 视网膜母细胞瘤 癌-睾丸抗原 肿瘤免疫治疗 |
| DOI：10.3969/j.issn.1674-3806.2011.09.01 |
| 分类号:R 739.7 |
| 基金项目:广西科技厅青年基金资助项目(编号：桂科青0542052)；广西卫生厅自筹经费科研课题（编号：桂卫Z2006049） |
|
| Expression of NY-SAR-35 in retinoblastoma and its clinical significance |
|
KONG Min,LIN Quan,LIANG Hao,et al.
|
|
Department of Ophthalmology,the First Affiliated Hospital of Guangxi Medical University, Nanning 530021,China
|
| Abstract: |
| ［Abstract］ Objective To detect the mRNA expression of the cancer testis antigens (NY-SAR-35) in retinoblastoma (RB) and investigate the possibility of applying these antigens as the target antigens for RB specific immunotherapy. Methods With reverse-transcription polymerase chain reaction (RT-PCR), the mRNA expression of NY-SAR-35 in 15 cases of RB tissues, 12 cases of nontumorous′ retina tissues and 22 cases of other ocular region normal tissues(12 cases of blepharo-cutis, 5 cases of musculi oculi and 5 cases of conjunctiva) was detected. Samples selected randomly from PCR positive products of each CT gene were directly sequenced. The results of expression and related clinical parameters(sex, age, patho-typing, tumorous size, clinical stage) were analyzed with statistic analysis software. Results Among 15 RB tissues, NY-SAR-35 mRNA was detected in 60%（95%CI： 35.2%～84.8%）, and NY-SAR-35 mRNA can not be detected in both nontumorous′ region and other ocular region normal tissues. Conclusion NY-SAR-35 is expressed specifically in RB. So NY-SAR-35 may become special target antigen of immunity treatment. This result is worth further study. |
| Key words: Retinoblastoma Cancer testis antigen Cancer immunotherapy |
